The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales

Eoghan Mccarthy; Emily Sutton; Stephanie Nesbit; Benjamin Parker; David Jayne; Bridget Griffiths; D. Isenberg; Anisur Rahman; Caroline Gordon; David P D'Cruz; B. Rhodes; Peter Lanyon; Edward M Vital; Chee-Seng Yee; Christopher Edwards; Lee-Suan Teh; Mohammed Akil; Neil J.  McHugh; Asad Zoma; Ian Bruce

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales

Eoghan Mccarthy, Emily Sutton, Stephanie Nesbit, Benjamin Parker, David Jayne, Bridget Griffiths, D. Isenberg, Anisur Rahman, Caroline Gordon, David P D'Cruz, B. Rhodes, Peter Lanyon, Edward M Vital, Chee-Seng Yee, Christopher Edwards, Lee-Suan Teh, Mohammed Akil, Neil J. McHugh, Asad Zoma, Ian Bruce

Division of Musculoskeletal & Dermatological Sciences (L5)

Bath Institute of Rheumatic Diseases

Research output: Contribution to journal › Letter

Original language	English
Pages (from-to)	1041-1043
Journal	Rheumatology
Volume	56
Issue number	6
Publication status	Published - 2017

Embargoed Document

FinalBelimumabLetterRheumatology23-11-16
Accepted author manuscript, 102 KB
Embargo ends: 1/01/26

Cite this

Mccarthy, E., Sutton, E., Nesbit, S., Parker, B., Jayne, D., Griffiths, B., Isenberg, D., Rahman, A., Gordon, C., D'Cruz, D. P., Rhodes, B., Lanyon, P., Vital, E. M., Yee, C.-S., Edwards, C., Teh, L.-S., Akil, M., McHugh, N. J., Zoma, A., & Bruce, I. (2017). The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales. Rheumatology, 56(6), 1041-1043.

@article{4fb7e4d5ffcc4ead9837ee07e10aaa97,

title = "The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales",

author = "Eoghan Mccarthy and Emily Sutton and Stephanie Nesbit and Benjamin Parker and David Jayne and Bridget Griffiths and D. Isenberg and Anisur Rahman and Caroline Gordon and D'Cruz, {David P} and B. Rhodes and Peter Lanyon and Vital, {Edward M} and Chee-Seng Yee and Christopher Edwards and Lee-Suan Teh and Mohammed Akil and McHugh, {Neil J.} and Asad Zoma and Ian Bruce",

year = "2017",

language = "English",

volume = "56",

pages = "1041--1043",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "6",

}

Mccarthy, E, Sutton, E, Nesbit, S, Parker, B, Jayne, D, Griffiths, B, Isenberg, D, Rahman, A, Gordon, C, D'Cruz, DP, Rhodes, B, Lanyon, P, Vital, EM, Yee, C-S, Edwards, C, Teh, L-S, Akil, M, McHugh, NJ, Zoma, A & Bruce, I 2017, 'The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales', Rheumatology, vol. 56, no. 6, pp. 1041-1043.

TY - JOUR

T1 - The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales

AU - Mccarthy, Eoghan

AU - Sutton, Emily

AU - Nesbit, Stephanie

AU - Parker, Benjamin

AU - Jayne, David

AU - Griffiths, Bridget

AU - Isenberg, D.

AU - Rahman, Anisur

AU - Gordon, Caroline

AU - D'Cruz, David P

AU - Rhodes, B.

AU - Lanyon, Peter

AU - Vital, Edward M

AU - Yee, Chee-Seng

AU - Edwards, Christopher

AU - Teh, Lee-Suan

AU - Akil, Mohammed

AU - McHugh, Neil J.

AU - Zoma, Asad

AU - Bruce, Ian

PY - 2017

Y1 - 2017

M3 - Letter

SN - 1462-0324

VL - 56

SP - 1041

EP - 1043

JO - Rheumatology

JF - Rheumatology

IS - 6

ER -